Immunocompetent murine models for the study of glioblastoma immunotherapy

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Oh, Taemin ^a   Fakurnejad, Shayan ^a   Sayegh, Eli T ^a   Clark, Aaron J ^b   Ivan, Michael E ^b   Sun, Matthew Z ^b   Safaee, Michael ^b   Bloch, Orin ^a   James, Charles D ^b   Parsa, Andrew T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Astrocytoma; Glioblastoma; Glioma; Immune response; Immunosuppression; Immunotherapy; Murine; Preclinical

Indexed keywords

3 METHYLCHOLANTHRENE; CD133 ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE AMMONIA LIGASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; MELANOMA ANTIGEN; PLASMID VECTOR; PROTEIN S 100; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL LYSATE; CELL THERAPY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE MODEL; DRUG EFFICACY; DRUG POTENTIATION; GLIOBLASTOMA; IMMUNOCOMPETENCE; IMMUNOGENICITY; IN VIVO STUDY; MOUSE MODEL; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; TRANSGENIC MOUSE; TREATMENT RESPONSE; ANIMAL; BRAIN NEOPLASMS; IMMUNOTHERAPY; MOUSE;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; IMMUNOCOMPETENCE; IMMUNOTHERAPY; MICE;

EID: 84899968056     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-107     Document Type: Review

References (125)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, . European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group.
2. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011, 29:4828-4836. 10.1200/JCO.2011.38.0899, 3255990, 22042955.
3. Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT, Mitchell DA, Fecci PE, Sampson JH, Dranoff G. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines 2013, 12:597-615. 10.1586/erv.13.41, 23750791.
4. Bovenberg MS, Degeling MH, Tannous BA. Cell-based immunotherapy against gliomas: from bench to bedside. Mol Ther 2013, 21:1297-1305. 10.1038/mt.2013.80, 23648695.
5. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570. 10.1126/science.1203486, 21436444.
6. Aguilar LK, Arvizu M, Aguilar-Cordova E, Chiocca EA. The spectrum of vaccine therapies for patients with glioblastoma multiforme. Curr Treat Options Oncol 2012, 13:437-450. 10.1007/s11864-012-0208-2, 3499675, 22903697.
7. Mohme M, Neidert MC, Regli L, Weller M, Martin R. Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer Treat Rev 2014, 40:248-258. 10.1016/j.ctrv.2013.08.008, 24064197.
8. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. Neuro Oncol 2011, 13:3-13. 10.1093/neuonc/noq169, 3018912, 21149252.
9. Denysenko T, Gennero L, Roos MA, Melcarne A, Juenemann C, Faccani G, Morra I, Cavallo G, Reguzzi S, Pescarmona G, Ponzetto A. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem Funct 2010, 28:343-351. 10.1002/cbf.1666, 20535838.
10. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007, 13:84-88. 10.1038/nm1517, 17159987.
11. Barth RF, Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 2009, 94:299-312. 10.1007/s11060-009-9875-7, 2730996, 19381449.
12. Peterson DL, Sheridan PJ, Brown WE. Animal models for brain tumors: historical perspectives and future directions. J Neurosurg 1994, 80:865-876. 10.3171/jns.1994.80.5.0865, 8169627.
13. Serano RD, Pegram CN, Bigner DD. Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta Neuropathol 1980, 51:53-64. 10.1007/BF00688850, 7435141.
14. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976, 33:241-259. 10.1038/bjc.1976.37, 2024987, 773395.
15. Seligman AM, Shear M, Alexander L. Studies in Carcinogenesis: VIII. Experimental Production of Brain Tumors in Mice with Methylcholanthrene. Am J Cancer 1939, 37:364-395.
16. Sonabend AM, Ulasov IV, Lesniak MS. Emerging role of new transgenic mouse models in glioma research. Expert Rev Anticancer Ther 2007, 7:S7-S13. 10.1586/14737140.7.12s.S7, 18076321.
17. Hambardzumyan D, Parada LF, Holland EC, Charest A. Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 2011, 59:1155-1168. 10.1002/glia.21142, 3619979, 21305617.
18. Huse JT, Holland EC. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol 2009, 19:132-143. 10.1111/j.1750-3639.2008.00234.x, 2659383, 19076778.
19. Chow LM, Baker SJ. Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models. Oncotarget 2012, 3:67-77. 3292893, 22287481.
20. Sughrue ME, Yang I, Kane AJ, Rutkowski MJ, Fang S, James CD, Parsa AT. Immunological considerations of modern animal models of malignant primary brain tumors. J Transl Med 2009, 7:84. 10.1186/1479-5876-7-84, 2768693, 19814820.
21. Zimmerman HM, Arnold H. Experimental brain tumors I. Tumors produced with methylcholanthrene. Cancer Res 1941, 1:919-938.
22. Pantelouris EM. Absence of thymus in a mouse mutant. Nature 1968, 217:370-371. 10.1038/217370a0, 5639157.
23. Rana MW, Pinkerton H, Thornton H, Nagy D. Heterotransplantation of human glioblastoma multiforme and meningioma to nude mice. Proc Soc Exp Biol Med 1977, 155:85-88. 10.3181/00379727-155-39750, 193127.
24. Danks RA, Orian JM, Gonzales MF, Tan SS, Alexander B, Mikoshiba K, Kaye AH. Transformation of astrocytes in transgenic mice expressing SV40 T antigen under the transcriptional control of the glial fibrillary acidic protein promoter. Cancer Res 1995, 55:4302-4310.
25. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010, 16:474-485. 10.1158/1078-0432.CCR-09-1322, 3682507, 20068073.
26. Balyasnikova IV, Ferguson SD, Sengupta S, Han Y, Lesniak MS. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. PLoS One 2010, 5:e9750. 10.1371/journal.pone.0009750, 2841188, 20305783.
27. Ohno M, Natsume A, Ichiro Iwami K, Iwamizu H, Noritake K, Ito D, Toi Y, Ito M, Motomura K, Yoshida J, Yoshikawa K, Wakabayashi T. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci 2010, 101:2518-2524. 10.1111/j.1349-7006.2010.01734.x, 20880333.
28. Chen L, Zhang Y, Yang J, Hagan JP, Li M. Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. Biochim Biophys Acta 1836, 2013:158-165.
29. Rankin SL, Zhu G, Baker SJ. Review: insights gained from modelling high-grade glioma in the mouse. Neuropathol Appl Neurobiol 2012, 38:254-270. 10.1111/j.1365-2990.2011.01231.x, 3312987, 22035336.
30. Reilly KM, Jacks T. Genetically engineered mouse models of astrocytoma: GEMs in the rough?. Semin Cancer Biol 2001, 11:177-191. 10.1006/scbi.2000.0375, 11407943.
31. Fraser H. Astrocytomas in an inbred mouse strain. J Pathol 1971, 103:266-270. 10.1002/path.1711030410, 5563880.
32. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, Bigner DD, Sampson JH. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000, 103:16-25.
33. Pilkington GJ, Darling JL, Lantos PL, Thomas DG. Cell lines (VMDk) derived from a spontaneous murine astrocytoma. Morphological and immunocytochemical characterization. J Neurol Sci 1983, 62:115-139. 10.1016/0022-510X(83)90193-4, 6321667.
34. Pilkington GJ, Lantos PL, Darling JL, Thomas DG. Three cell lines from a spontaneous murine astrocytoma show variation in astrocytic differentiation. Neurosci Lett 1982, 34:315-320. 10.1016/0304-3940(82)90194-X, 6131401.
35. Sampson JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD. Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 1997, 41:1365-1372. discussion 1372-1363, 10.1097/00006123-199712000-00024, 9402588.
36. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A. Immunosuppression and transforming growth factor-beta in glioblastoma: Preferential production of transforming growth factor-beta 2. J Immunol 1989, 143:3222-3229.
37. Miller J, Eisele G, Tabatabai G, Aulwurm S, von Kurthy G, Stitz L, Roth P, Weller M. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. J Neurosurg 2010, 113:280-285. 10.3171/2009.11.JNS09901, 19961309.
38. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA. EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss. Clin Cancer Res 2014, 20:972-984. 10.1158/1078-0432.CCR-13-0709, 24352643.
39. Seyfried TN, el-Abbadi M, Roy ML. Ganglioside distribution in murine neural tumors. Mol Chem Neuropathol 1992, 17:147-167. 10.1007/BF03159989, 1418222.
40. Martinez-Murillo R, Martinez A. Standardization of an orthotopic mouse brain tumor model following transplantation of CT-2A astrocytoma cells. Histol Histopathol 2007, 22:1309-1326.
41. Binello E, Qadeer ZA, Kothari HP, Emdad L, Germano IM. Stemness of the CT-2A Immunocompetent Mouse Brain Tumor Model: Characterization In Vitro. J Cancer 2012, 3:166-174. 3328782, 22514559.
42. Abate LE, Mukherjee P, Seyfried TN. Gene-linked shift in ganglioside distribution influences growth and vascularity in a mouse astrocytoma. J Neurochem 2006, 98:1973-1984. 10.1111/j.1471-4159.2006.04097.x, 16911584.
43. Mukherjee P, Abate LE, Seyfried TN. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 2004, 10:5622-5629. 10.1158/1078-0432.CCR-04-0308, 15328205.
44. Shelton LM, Mukherjee P, Huysentruyt LC, Urits I, Rosenberg JA, Seyfried TN. A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion. J Neurooncol 2010, 99:165-176. 10.1007/s11060-010-0115-y, 20069342.
45. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK, Fine HA. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403. 10.1016/j.ccr.2006.03.030, 16697959.
46. Qiang L, Yang Y, Ma YJ, Chen FH, Zhang LB, Liu W, Qi Q, Lu N, Tao L, Wang XT, You QD, Guo QL. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 2009, 279:13-21. 10.1016/j.canlet.2009.01.016, 19232461.
47. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004, 23:9392-9400. 10.1038/sj.onc.1208311, 15558011.
48. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401. 10.1038/nature03128, 15549107.
49. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008, 14:123-129. 10.1158/1078-0432.CCR-07-0932, 18172261.
50. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De Maria R. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006, 13:1238-1241. 10.1038/sj.cdd.4401872, 16456578.
51. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007, 67:1-5. 10.1016/j.ijrobp.2006.09.037, 17084552.
52. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Sawaya R, Lang FF, Heimberger AB. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010, 16:461-473. 10.1158/1078-0432.CCR-09-1983, 2943842, 20068105.
53. Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, Sawaya R, Lang FF, Heimberger AB. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010, 9:67-78. 2939737, 20053772.
54. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012, 23:1043-1053. 10.1089/hum.2012.041, 3472555, 22780919.
55. Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, Barish ME, Forman SJ, Jensen MC. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res 2012, 18:2199-2209. 10.1158/1078-0432.CCR-11-1669, 3578382, 22407828.
56. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature 2008, 451:345-349. 10.1038/nature06489, 3660705, 18202660.
57. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174. 10.1038/nm1483, 16998484.
58. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006, 12:1175-1180. 10.1038/nm1489, 16998483.
59. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF, Sutherland MK, Gerber HP, Van Orden KL, Moore PA, Ruben SM, Carter PJ. CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008, 99:100-109. 10.1038/sj.bjc.6604437, 2453027, 18542072.
60. Wu A, Wiesner S, Xiao J, Ericson K, Chen W, Hall WA, Low WC, Ohlfest JR. Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J Neurooncol 2007, 83:121-131. 10.1007/s11060-006-9265-3, 17077937.
61. Marsh J, Mukherjee P, Seyfried TN. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res 2008, 14:7751-7762. 10.1158/1078-0432.CCR-08-0213, 19047102.
62. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999, 9:469-479. 10.1111/j.1750-3639.1999.tb00536.x, 10416987.
63. Waldron JS, Yang I, Han S, Tihan T, Sughrue ME, Mills SA, Pieper RO, Parsa AT. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. J Clin Neurosci 2010, 17:1543-1547. 10.1016/j.jocn.2010.04.021, 3795509, 20822910.
64. Ausman JI, Shapiro WR, Rall DP. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 1970, 30:2394-2400.
65. Szatmari T, Lumniczky K, Desaknai S, Trajcevski S, Hidvegi EJ, Hamada H, Safrany G. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006, 97:546-553. 10.1111/j.1349-7006.2006.00208.x, 16734735.
66. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR, Castro MG. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007, 85:133-148. 10.1007/s11060-007-9400-9, 2384236, 17874037.
67. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992, 355:846-847. 10.1038/355846a0, 1311419.
68. Trent J, Meltzer P, Rosenblum M, Harsh G, Kinzler K, Mashal R, Feinberg A, Vogelstein B. Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. Proc Natl Acad Sci U S A 1986, 83:470-473. 10.1073/pnas.83.2.470, 322881, 3001737.
69. Gururaj AE, Gibson L, Panchabhai S, Bai M, Manyam G, Lu Y, Latha K, Rojas ML, Hwang Y, Liang S, Bogler O. Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of DeltaEGFR/EGFRvIII. J Biol Chem 2013, 288:3428-3438. 10.1074/jbc.M112.399352, 3561561, 23250739.
70. Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R, Demaria S, Newcomb EW. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 2005, 85:328-341. 10.1038/labinvest.3700233, 15716863.
71. Anderson RC, Anderson DE, Elder JB, Brown MD, Mandigo CE, Parsa AT, Goodman RR, McKhann GM, Sisti MB, Bruce JN. Lack of B7 expression, not human leukocyte antigen expression, facilitates immune evasion by human malignant gliomas. Neurosurgery 2007, 60:1129-1136. discussion 1136.
72. Zagzag D, Amirnovin R, Greco MA, Yee H, Holash J, Wiegand SJ, Zabski S, Yancopoulos GD, Grumet M. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 2000, 80:837-849. 10.1038/labinvest.3780088, 10879735.
73. Vince GH, Bendszus M, Schweitzer T, Goldbrunner RH, Hildebrandt S, Tilgner J, Klein R, Solymosi L, Christian Tonn J, Roosen K. Spontaneous regression of experimental gliomas-an immunohistochemical and MRI study of the C6 glioma spheroid implantation model. Exp Neurol 2004, 190:478-485. 10.1016/j.expneurol.2004.08.015, 15530886.
74. Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 2011, 60:153-160. 10.1007/s00262-010-0946-6, 21120655.
75. Plautz GE, Touhalisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 1997, 178:101-107. 10.1006/cimm.1997.1140, 9225000.
76. Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001, 61:2031-2037.
77. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007, 13:2158-2167. 10.1158/1078-0432.CCR-06-2070, 17404100.
78. Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP. Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 1995, 83:1038-1044. 10.3171/jns.1995.83.6.1038, 7490618.
79. Keke F, Hongyang Z, Hui Q, Jixiao L, Jian C. A combination of flk1-based DNA vaccine and an immunomodulatory gene (IL-12) in the treatment of murine cancer. Cancer Biother Radiopharm 2004, 19:649-657. 10.1089/cbr.2004.19.649, 15650458.
80. Paul AK, Ciesielski MJ, Sajjad M, Wang X, Ferrone S, Abdel-Nabi H, Fenstermaker RA. Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J Neurooncol 2009, 94:21-30. 10.1007/s11060-009-9798-3, 2741310, 19152070.
81. Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med 2004, 2:40. 10.1186/1479-5876-2-40, 535538, 15563374.
82. Iizuka Y, Kojima H, Kobata T, Kawase T, Kawakami Y, Toda M. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. Int J Cancer 2006, 118:942-949. 10.1002/ijc.21432, 16152596.
83. Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, Fenstermaker RA. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 2006, 55:1491-1503. 10.1007/s00262-006-0138-6, 16485128.
84. Ni HT, Spellman SR, Jean WC, Hall WA, Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001, 51:1-9. 10.1023/A:1006452726391, 11349874.
85. Pellegatta S, Poliani PL, Corno D, Grisoli M, Cusimano M, Ubiali F, Baggi F, Bruzzone MG, Finocchiaro G. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 2006, 28:527-531. 10.1179/016164106X116809, 16808884.
86. Jiang XB, Lu XL, Hu P, Liu RE. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine 2009, 27:6210-6216. 10.1016/j.vaccine.2009.08.002, 19699331.
87. Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 2009, 11:529-542. 10.1215/15228517-2009-004, 2765342, 19336528.
88. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009, 15:6551-6559. 10.1158/1078-0432.CCR-09-1067, 2783346, 19861464.
89. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001, 29:117-129. 10.1038/ng1001-117, 11586292.
90. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, Khazaie K. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A 2005, 102:419-424. 10.1073/pnas.0408197102, 544311, 15623559.
91. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004, 30:193-204. 10.1016/j.ctrv.2003.07.007, 15023437.
92. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
93. Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, Lin Y, Dietz AB, Forsyth PA, Yong VW, Parney IF. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010, 12:351-365. 10.1093/neuonc/nop023, 2940603, 20308313.
94. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages. Clin Cancer Res 2013, 19:3165-3175. 10.1158/1078-0432.CCR-12-3314, 23613317.
95. Crane C, Panner A, Pieper RO, Arbiser J, Parsa AT. Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother 2009, 32:585-592. 10.1097/CJI.0b013e3181a8efe6, 3795513, 19483651.
96. Wu A, Oh S, Wiesner SM, Ericson K, Chen L, Hall WA, Champoux PE, Low WC, Ohlfest JR. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 2008, 17:173-184. 10.1089/scd.2007.0133, 18271701.
97. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, Suarez-Merino B, Caldera V, Nava S, Ravanini M, Facchetti F, Bruzzone MG, Finocchiaro G. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006, 66:10247-10252. 10.1158/0008-5472.CAN-06-2048, 17079441.
98. Xu M, Yao Y, Hua W, Wu Z, Zhong P, Mao Y, Zhou L, Luo F, Chu Y. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells. J Neurooncol 2014, 116:497-504. 10.1007/s11060-013-1334-9, 24398615.
99. Crane CA, Ahn BJ, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol 2012, 14:584-595. 10.1093/neuonc/nos014, 3337302, 22406925.
100. Akbasak A, Oldfield EH, Saris SC. Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J Neurosurg 1991, 75:922-929. 10.3171/jns.1991.75.6.0922, 1941122.
101. Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003, 63:8487-8491.
102. Kim CH, Hong MJ, Park SD, Kim CK, Park MY, Sohn HJ, Cho HI, Kim TG, Hong YK. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother 2006, 55:1309-1319. 10.1007/s00262-006-0134-x, 16463038.
103. Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, Lowenstein PR, Castro MG. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One 2008, 3:e1983. 10.1371/journal.pone.0001983, 2291560, 18431473.
104. Park SD, Kim CH, Kim CK, Park JA, Sohn HJ, Hong YK, Kim TG. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 2007, 25:3485-3491. 10.1016/j.vaccine.2006.12.060, 17275143.
105. Kim TG, Kim CH, Park JS, Park SD, Kim CK, Chung DS, Hong YK. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 2010, 17:143-153. 10.1128/CVI.00292-09, 2812079, 19889936.
106. Weiner NE, Pyles RB, Chalk CL, Balko MG, Miller MA, Dyer CA, Warnick RE, Parysek LM. A syngeneic mouse glioma model for study of glioblastoma therapy. J Neuropathol Exp Neurol 1999, 58:54-60. 10.1097/00005072-199901000-00007, 10068314.
107. Dyer CA, Philibotte T. A clone of the MOCH-1 glial tumor in culture: multiple phenotypes expressed under different environmental conditions. J Neuropathol Exp Neurol 1995, 54:852-863. 10.1097/00005072-199511000-00012, 7595658.
108. Higgins RJ, McKisic M, Dickinson PJ, Jimenez DF, Dow SW, Tripp LD, LeCouteur RA. Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Cancer Immunol Immunother 2004, 53:338-344. 10.1007/s00262-003-0447-y, 14618278.
109. Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 2005, 7:213-224. 10.1215/S1152851705000074, 1871915, 16053696.
110. Markert JM, Cody JJ, Parker JN, Coleman JM, Price KH, Kern ER, Quenelle DC, Lakeman AD, Schoeb TR, Palmer CA, Cartner SC, Gillespie GY, Whitley RJ. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol 2012, 86:5304-5313. 10.1128/JVI.06998-11, 3347348, 22379082.
111. Newcomb EW, Zagzag D. The murine GL261 glioma experimental model to assess novel brain tumor treatments. CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches 2009, 227-241. New York: Springer, Van Meir EG.
112. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008, 14:3098-3104. 10.1158/1078-0432.CCR-07-4875, 18483377.
113. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009, 8:2773-2779. 10.1158/1535-7163.MCT-09-0124, 2991139, 19825799.
114. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008, 20:267-275. 10.1016/j.smim.2008.04.001, 2633865, 18539480.
115. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, Catala Ferrer M, Bravo I, del Pino Mendoza M, Abreu Abreu D, Acosta Brooks S, Rives R, del Castillo Carrillo C, González Dueñas M, Viada C, García Verdecia B, Crombet Ramos T, González Marinello G, Lage Dávila A. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:1452-1458. 10.1200/JCO.2007.11.5980, 18349395.
116. Saito R, Mizuno M, Nakahara N, Tsuno T, Kumabe T, Yoshimoto T, Yoshida J. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int J Cancer 2004, 111:777-782. 10.1002/ijc.20331, 15252850.
117. Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther 2004, 11:1551-1558. 10.1038/sj.gt.3302300, 15343358.
118. Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T, Sakaida T, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Storkus WJ, Okada H. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 2005, 175:2730-2740. 10.4049/jimmunol.175.4.2730, 16081851.
119. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003, 9:4247-4254.
120. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J, Wurm G, Mehdorn M, Strege R, Schuierer G, Villarrubia V, Fellner F, Jansen O, Straube T, Nohria V, Goldbrunner M, Kunst M, Schmaus S, Stauder G, Bogdahn U, Schlingensiepen KH. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007, 17:201-212. 10.1089/oli.2006.0053, 17638524.
121. Jaschinski F, Rothhammer T, Jachimczak P, Seitz C, Schneider A, Schlingensiepen KH. The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-beta2. Curr Pharm Biotechnol 2011, 12:2203-2213. 10.2174/138920111798808266, 21619536.
122. Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K, Hamilton A, DeMasters BK, Judy K, Kirn D. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 2008, 16:618-626. 10.1038/sj.mt.6300396, 18180770.
123. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004, 64:7954-7961. 10.1158/0008-5472.CAN-04-1013, 15520202.
124. Spagnolo A, Glick RP, Lin H, Cohen EP, Feinstein DL, Lichtor T. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts. J Neurosurg 2007, 106:299-305. 10.3171/jns.2007.106.2.299, 17410715.
125. Natsume A, Mizuno M, Ryuke Y, Yoshida J. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 1999, 6:1626-1633. 10.1038/sj.gt.3300990, 10490773.